Avacta Therapeutics (AIM: AVCT) has launched an accelerated bookbuild and subscription seeking minimum gross proceeds of approximately £12.5 million.

Avacta (AIM: AVCT) currently expects its existing cash resources to last into early Q1 2027 and is continuing discussions with potential partners for its next-generation assets.

Avacta Therapeutics (AIM: AVCT) has presented the design of its Phase 1 FOCUS-01 trial and updated preclinical data supporting AVA6103 in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic

Avacta Therapeutics (AIM: AVCT) has reported clinical proof of mechanism for AVA6103, its next-generation pre|CISION® peptide-drug conjugate, from the ongoing Phase 1 FOCUS-01 trial.

  Avacta Therapeutics (AIM: AVCT) has appointed experienced biotechnology finance executive Mats Blom to its Board of Directors, where he will also serve as Chair of the Audit Committee.

Avacta Therapeutics (AIM: AVCT) has settled an accelerated deferred convertible bond repayment of £2.613 million in cash, reducing the remaining principal under the facility to £12 million.

Avacta (AIM: AVCT) has granted a substantial package of share options to its management team, including 13.4 million options to chief executive Christina Coughlin, as part of an incentive and

Accelerated Amortized Payment of Convertible Bond Installment

Avacta Therapeutics (AIM: AVCT) has appointed healthcare executive Dr Patrick Vink to its board as non-executive deputy chairman and senior independent director.

Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer

Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.